Halozyme Therapeutics (NASDAQ:HALO) Downgraded to Hold Rating by Wall Street Zen
Halozyme Therapeutics (NASDAQ:HALO) has been downgraded from a "strong-buy" to a "hold" rating by Wall Street Zen. This follows Halozyme's recent earnings report where it missed EPS consensus but slightly exceeded revenue expectations. Despite the downgrade, the company still holds a "Moderate Buy" consensus rating from analysts with an average price target of $78.56.
Jupiter Asset Management Ltd. Purchases 129,971 Shares of Halozyme Therapeutics, Inc. $HALO
Jupiter Asset Management Ltd. increased its holdings in Halozyme Therapeutics (NASDAQ:HALO) by 19.4%, now owning 800,583 shares valued at approximately $58.7 million. This move comes despite recent insider selling by the company's director and CEO, totaling over $3.6 million in the last three months. Halozyme also reported a mixed earnings quarter, missing EPS estimates but exceeding revenue expectations with a 51.6% year-over-year increase, while analysts maintain a "Moderate Buy" rating with a $78.56 consensus price target.
Halozyme Therapeutics Reports Significant 2025 Growth
Halozyme Therapeutics reported significant growth in 2025, driven by accelerating royalty revenue from ENHANZE-enabled products, portfolio expansion into new subcutaneous drug delivery technologies, and new collaborations. The company achieved record revenue growth of 38% to $1.4 billion and expects to sign at least three new licensing agreements in 2026. Halozyme's ENHANZE technology improves patient access and convenience by enabling subcutaneous administration of biologic therapies.
Halozyme Therapeutics Reports Q4 Earnings
Halozyme Therapeutics, a San Diego-based biopharmaceutical company, reported a Q4 loss of $141.6 million, or $1.20 per share, missing analyst expectations. However, the company exceeded revenue forecasts with $451.8 million in the period. For the full year, Halozyme reported profits of $316.9 million and expects 2026 full-year earnings between $7.75 to $8.25 per share and revenue from $1.71 billion to $1.81 billion.
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $90.00
Benchmark has increased its price target for Halozyme Therapeutics (NASDAQ:HALO) to $90.00 from $75.00, reiterating a "buy" rating and suggesting a potential upside of 25.76%. This comes despite a Q4 GAAP EPS miss due to acquisition charges, as the company reported a revenue beat and strong FY2025 results with positive 2026 guidance. While insider selling has occurred, large institutional investors have significantly increased their stakes in the biopharmaceutical company.
Benchmark raises Halozyme stock price target to $90 on strong results
Benchmark has increased its stock price target for Halozyme Therapeutics Inc. to $90 from $75, maintaining a Buy rating after the company reported strong fourth-quarter 2025 revenues of $451.8 million, a 52% increase year-over-year. Despite a non-GAAP diluted loss per share due to acquisition-related write-offs, non-GAAP earnings before charges significantly exceeded the previous year. This positive outlook is further supported by TD Cowen, which also raised its price target to $96, citing strong royalty growth.
Halozyme (HALO) Loses 9% on Weak Earnings
Halozyme Therapeutics Inc. (NASDAQ:HALO) saw its stock price drop by 9.01% after reporting weak earnings for both the fourth quarter and full-year 2025. Despite a 37% increase in revenues to $1.396 billion for the full year, net income fell by 28.6% to $317 million. The company aims for revenues between $1.71 billion and $1.81 billion this year, with a target of $2 billion by 2028.
Halozyme (HALO) Loses 9% on Weak Earnings
Halozyme Therapeutics Inc. (HALO) saw its stock drop by 9.01% after reporting weak earnings for both Q4 and the full year 2025. Despite a 37% surge in revenues to $1.396 billion for the year, net income fell by 28.6% to $317 million. The company expects revenues between $1.71 billion and $1.81 billion for 2026.
Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8.7% Following Weak Earnings
Halozyme Therapeutics (NASDAQ:HALO) saw its stock price drop 8.7% after reporting a surprising GAAP loss of ($0.24) EPS, significantly missing a consensus estimate of $1.92. Despite the earnings miss, the company's Q4 revenue slightly exceeded estimates, and it posted record full-year 2025 revenue of $1.397 billion with strong 2026 guidance. The sell-off was fueled by the unexpected loss, rising liabilities, margin pressure, insider selling, and mixed analyst views, even with robust royalty growth and significant institutional ownership.
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues
Halozyme (HALO) reported a Q4 2025 adjusted loss of 24 cents per share, missing the Zacks Consensus Estimate, primarily due to acquired IPR&D expenses. Despite the earnings miss, total revenues increased 52% year-over-year to $451.8 million, surpassing estimates, driven by strong product sales and higher royalty payments from its Enhanze technology. The company also reiterated its 2026 revenue guidance, projecting significant year-over-year growth in royalties and adjusted EBITDA.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. reported its Q4 and full-year 2025 financial and operating results, highlighting a year of significant growth with total revenue up 38% to $1.4 billion and royalty revenue increasing 52% to $868 million. The company expanded its drug delivery portfolio through acquisitions of Hypercon and Surf Bio technologies, broadening its collaboration opportunities. Halozyme also discussed the strong performance of ENHANZE-enabled products like DARZALEX, PHESGO, and VYVGART Hytrulo, along with projections for continued revenue growth and strategic initiatives for long-term value creation into the 2040s.
Halozyme Q4 2025 Earnings Surge: Royalty Revenue Soars 52%
Halozyme Therapeutics Inc. reported record revenues for Q4 and full-year 2025, with total annual revenue reaching $1.4 billion, a 38% year-over-year growth, and royalty revenue soaring 52% to $868 million. The company's ENHANZE technology and key partnerships are identified as significant drivers, with a positive outlook for 2026 projecting sales of $1.710-$1.810 billion and a substantial increase in EBITDA.
Halozyme 2025 Earnings: Revenue Up 51.6%, Guides for 2026 EPS of $8 - News and Statistics
Halozyme Therapeutics reported 2025 Q4 revenue of $451.8 million, a 51.6% increase year-over-year, beating analyst expectations. Despite strong revenue, the company posted a non-GAAP loss per share of $0.24 and an adjusted EBITDA significantly below estimates due to $284.9 million in acquired in-process R&D expenses from the Surf Bio acquisition. For 2026, Halozyme forecasts adjusted EPS of $8 and EBITDA of $1.17 billion, both slightly missing analyst predictions.
Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales
Halozyme Therapeutics (NASDAQ:HALO) reported Q4 CY2025 revenue of $451.8 million, exceeding Wall Street expectations, but its non-GAAP loss of $0.24 per share significantly missed estimates. The company's full-year 2026 adjusted EPS and EBITDA guidance also fell short of analyst forecasts, mainly due to a significant acquired IPR&D expense related to the Surf Bio acquisition. Despite strong historical revenue growth, operating margins declined, and the stock traded down following the results.
Halozyme Therapeutics: Fourth Quarter Earnings Overview
Halozyme Therapeutics reported a net loss of $141.6 million for the fourth quarter, or $1.20 per share, which adjusted to a loss of 24 cents per share. This fell short of analyst expectations of $2.15 per share. Despite the earnings miss, the company's revenue for the quarter reached $451.8 million, exceeding the anticipated $448.6 million, and its full-year profit was $316.9 million with $1.4 billion in revenue. Halozyme projects future earnings between $7.75 and $8.25 per share, with revenue between $1.71 billion and $1.81 billion.
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) reported a Q4 loss of $0.24 per share, missing the Zacks Consensus Estimate of $2.15, but exceeded revenue expectations with $451.77 million. Despite the earnings miss, the company has topped revenue estimates for the last four quarters. The stock currently holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the market.
Halozyme Therapeutics: Q4 Earnings Snapshot
Halozyme Therapeutics Inc. reported a Q4 loss of $141.6 million, or $1.20 per share, missing Wall Street's earnings expectations. The biopharmaceutical company did, however, exceed revenue forecasts with $451.8 million in the period. For the full year, Halozyme reported a profit of $316.9 million on $1.4 billion in revenue and provided guidance for 2026 earnings and revenue.
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) reported a Q4 loss of $0.24 per share, significantly missing the Zacks Consensus Estimate of $2.15, but surpassed revenue expectations with $451.77 million. Despite the earnings miss, the company has topped revenue estimates in the last four quarters and has seen its shares add about 18% year-to-date. The stock currently holds a Zacks Rank #3 (Hold) based on mixed estimate revisions.
Halozyme earnings in focus: Can royalty momentum carry into 2026?
Halozyme Therapeutics Inc. is set to announce its fourth-quarter earnings, with analysts anticipating strong performance and focusing on the company’s ability to sustain growth, particularly royalty revenue, beyond 2026. Investors will scrutinize Q4 royalty performance from key products and updates on new licensing agreements. There is debate among analysts regarding the company's long-term growth trajectory, with some expressing concerns about slowing royalty revenue in the 2030s, while others point to recent acquisitions extending intellectual property protection.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): A GARP Stock with Strong Growth and Reasonable Valuation
This article highlights Halozyme Therapeutics Inc. (NASDAQ:HALO) as a strong "Growth at a Reasonable Price" (GARP) stock candidate. The company, focused on its ENHANZE drug delivery technology, demonstrates robust revenue and EPS growth, with promising future projections. Its valuation metrics, particularly P/E and forward P/E, appear attractive compared to industry peers and the broader market, supported by strong earnings and financial fundamentals.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Thirteen brokerages have issued a "Moderate Buy" consensus rating for Halozyme Therapeutics, Inc. (NASDAQ:HALO), with an average 12-month target price of $78.80. The company's stock opened at $79.44, has a market capitalization of $9.34 billion, and a P/E ratio of 16.72. Insider transactions indicate recent sales by a director and the CEO, while institutional investors hold approximately 97.79% of the shares.
Halozyme Therapeutics Q4 Earnings Preview
Halozyme Therapeutics (HALO) is poised to release its Q4 earnings on February 17th, with analysts anticipating a robust 74.6% year-over-year EPS growth to $2.20 and a 49.7% rise in revenue to $446.13 million. The company has a strong record of beating EPS and revenue estimates, and recent upward revisions reflect analysts' optimistic outlook. Despite a recent slight price target downgrade by Morgan Stanley, TD Cowen upgraded its target, signaling continued market confidence.
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
A $1000 investment in Halozyme Therapeutics (HALO) made ten years ago would now be worth $10,535.81, representing a gain of 953.58%, excluding dividends. This significantly outperforms the S&P 500 and gold over the same period. The company's growth is driven by its ENHANZE technology collaborations, although biosimilar competition and dependence on partners pose potential risks.
Earnings Preview: Halozyme Therapeutics
Halozyme Therapeutics (NASDAQ: HALO) is scheduled to release its quarterly earnings on Tuesday, February 17, 2026, with analysts expecting an EPS of $2.15. Investors are looking for the company to surpass estimates and provide positive guidance. The company's stock has performed well, up 37.2% over the last 52 weeks, and investors are generally optimistic ahead of the announcement.
Rhumbline Advisers Trims Position in Halozyme Therapeutics, Inc. $HALO
Rhumbline Advisers reduced its stake in Halozyme Therapeutics (NASDAQ:HALO) by 4.6% in the third quarter of 2026, selling 17,487 shares, though institutional investors still hold a significant 97.79% of the company's stock. Despite the trim by Rhumbline, other hedge funds increased their positions, and Wall Street analysts generally maintain a "Moderate Buy" rating with an average target price of $78.80. Insider activity shows recent sales by CEO Helen Torley and Director Bernadette Connaughton, totaling over $1.6 million.
Envestnet Asset Management Inc. Cuts Stake in Halozyme Therapeutics, Inc. $HALO
Envestnet Asset Management Inc. reduced its stake in Halozyme Therapeutics by 8.6% in the third quarter, decreasing its shares to 246,478. Despite this reduction, several other large institutional investors significantly increased or initiated stakes in Halozyme, with overall institutional ownership remaining high at 97.79%. Analysts maintain a "Moderate Buy" consensus rating for HALO, with an average price target of $78.80, even as insiders have sold a notable amount of shares recently.
Is It Too Late To Consider Halozyme Therapeutics (HALO) After A 36% One Year Gain?
Halozyme Therapeutics (HALO) has seen a 36.3% gain over the last year, with its stock currently trading around US$79.44. Despite this increase, a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 62.0%, implying an intrinsic value of approximately $209.15 per share. The company's P/E ratio of 15.69x is also below both the industry average and Simply Wall St's estimated Fair Ratio, further suggesting it may be undervalued.
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know
Shares of Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health soared after a softer-than-expected inflation report increased hopes for Federal Reserve interest rate cuts. The January Consumer Price Index rose 0.2%, with the annual rate cooling to 2.4%, suggesting the Fed might ease its monetary policy sooner than anticipated. This news led to a market rally, with several healthcare stocks experiencing significant jumps.
Halozyme Biotech Acquisitions And M&A Plan Weigh On Valuation Case
Halozyme Therapeutics (NasdaqGS:HALO) has acquired three biotech startups, signaling a strategic shift towards growth through transactions and broader market penetration. This move, coupled with CEO commentary on M&A, is significant given the current consolidation trend in the biotech sector. Investors are advised to consider how these acquisitions and the company's clear M&A playbook will impact its future pipeline, revenue, and existing debt levels.
ING Groep NV Acquires New Stake in Halozyme Therapeutics, Inc. $HALO
ING Groep NV has acquired a new stake of 90,700 shares in Halozyme Therapeutics (NASDAQ:HALO), valued at approximately $6.65 million, representing 0.08% ownership. This move is part of broader institutional activity, with hedge funds and other investors owning nearly 98% of the company's stock. Analysts generally maintain a "Moderate Buy" rating with a consensus price target of $78.80 for the biopharmaceutical company.
Halozyme Biotech Acquisitions And M&A Plan Weigh On Valuation Case
Halozyme Therapeutics has acquired three biotech startups and shared its M&A strategy, signaling a push for growth through external transactions. While the deals indicate positive momentum and the company's shares appear undervalued according to Simply Wall St, investors should consider the impact of these acquisitions on Halozyme's financial health due to its existing high debt levels. The article emphasizes monitoring integration, deal costs, and the company's balance sheet going forward.
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
Halozyme Therapeutics, Inc. announced it will release its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, after the close of trading. The company will host a conference call on the same day at 1:30 PM PT/4:30 PM ET to discuss these results. Halozyme is a biopharmaceutical company known for its ENHANZE® drug delivery technology and is headquartered in San Diego, CA.
Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth
Halozyme Therapeutics (HALO) is projected to show significant year-over-year earnings and revenue growth for the quarter ended December 2025. Wall Street analysts expect quarterly earnings of $2.15 per share, representing a 70.6% increase, and revenues of $448.62 million, up 50.5%. However, with an Earnings ESP of 0% and a Zacks Rank #3, a conclusive earnings beat is not certain, despite a strong history of surpassing EPS estimates in the last four quarters.
Why Halozyme Therapeutics (HALO) Is Up 8.1% After Raising 2026 Revenue Guidance to up to $1.81 Billion
Halozyme Therapeutics (HALO) saw an 8.1% share price increase after raising its 2026 revenue guidance to between US$1.71 billion and US$1.81 billion, up from prior estimates. This optimistic outlook is driven by strong demand for its ENHANZE-enabled subcutaneous delivery partnerships, reinforcing the platform's scalability. However, the increased guidance also elevates execution risks related to partner launches, Halozyme's significant leverage, and potential slowdowns in royalty momentum.
Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth
Halozyme Therapeutics (HALO) is projected to show significant year-over-year earnings and revenue growth for Q4, with Wall Street analysts expecting $2.15 EPS and $448.62 million in revenue. Despite a positive revision trend in EPS estimates, the company's 0% Earnings ESP combined with a Zacks Rank #3 makes it difficult to definitively predict an earnings beat. Investors are advised to consider other factors alongside the strong past performance of beating EPS estimates for four consecutive quarters.
Profund Advisors LLC Trims Stock Holdings in Halozyme Therapeutics, Inc. $HALO
Profund Advisors LLC reduced its stake in Halozyme Therapeutics (NASDAQ:HALO) by 35.9% in the third quarter, while other institutional investors significantly increased their holdings. Analyst ratings for HALO are mixed, with a consensus "Hold" rating and an average target price of $78.80. Insider selling has also been noted, with CEO Helen Torley selling 10,000 shares recently.
Halozyme Therapeutics (HALO) to Release Earnings on Tuesday
Halozyme Therapeutics (NASDAQ:HALO) is scheduled to release its earnings report before market open on Tuesday, February 17th, with analysts expecting $1.92 per share. The company's stock opened at $80.48, and recent insider activity shows sales by a director and the CEO. Institutional investors have significantly increased their positions in the biopharmaceutical company, while analysts have issued a range of ratings with a consensus "Hold" and a target price of $78.80.
Halozyme Expecting Decade of Growth
Halozyme Therapeutics anticipates surpassing $1 billion in royalty revenue in 2026, a year earlier than projected, driven by its ENHANZE drug delivery system. The company expects significant year-over-year growth and plans to add more ENHANZE-enabled therapeutics and pursue strategic mergers and acquisitions to further bolster its product portfolio and revenue streams. Halozyme's revenue projections extend into the 2040s, based on existing and future drug partnerships.
Halozyme Therapeutics stock hits all-time high at 79.99 USD
Halozyme Therapeutics stock has reached an all-time high of $79.99, demonstrating robust performance with a 37.34% appreciation over the past year and an "EXCELLENT" financial health score. The biopharmaceutical firm's growth is supported by strategic initiatives, strong revenue guidance exceeding consensus estimates for FY25-FY28, and significant partnerships for its ENHANZE drug delivery technology. Analyst ratings are mixed, with Benchmark and H.C. Wainwright recommending "Buy," while Goldman Sachs maintains a "Sell" rating.
Assessing Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance
Halozyme Therapeutics (HALO) has significantly raised its revenue outlook for both 2025 and 2026, with the 2026 forecast now ranging from US$1.71 billion to US$1.81 billion, marking a 36% to 38% year-on-year growth. Despite a strong recent share price performance, the article discusses whether the stock remains undervalued or if its current price of $81.23 already reflects this growth, noting that a narrative model suggests HALO is overvalued at $77.13, while its P/E ratio is lower than peers and its own fair ratio. Key considerations include potential ENHANZE patent challenges and reliance on major partners.
Assessing Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance
Halozyme Therapeutics (HALO) has raised its revenue guidance for 2025 and 2026, projecting US$1.385b to US$1.40b for 2025 and US$1.71b to US$1.81b for 2026. Despite a recent strong share price performance, Simply Wall St's narrative model suggests the stock is currently overvalued at $81.23 compared to a fair value of $77.13. However, its P/E ratio of 16x is below its peers and industry, potentially indicating an undervalued opportunity or market caution due to inherent risks like ENHANZE patent challenges.
Halozyme Therapeutics stock hits all-time high at 79.99 USD By Investing.com
Halozyme Therapeutics Inc. stock reached an all-time high of $79.99, reflecting a 37.34% appreciation over the past year and an "EXCELLENT" financial health score, according to InvestingPro data. The company has revised its FY25 total revenue guidance upwards and provided strong revenue projections for 2026-2028, driven by strategic collaborations and milestones. Despite a "Sell" rating from Goldman Sachs, Benchmark and H.C. Wainwright have reiterated "Buy" ratings, highlighting investor confidence in its innovative drug delivery technologies and growth potential.
Halozyme Therapeutics stock hits all-time high at 79.99 USD By Investing.com
Halozyme Therapeutics (NASDAQ: HALO) stock reached an all-time high of $79.99, marking a 37.34% appreciation over the past year and indicating "EXCELLENT" financial health with 31.19% revenue growth according to InvestingPro. The company has revised its FY25 revenue guidance upwards and provided strong projections for 2026-2028, driven by strategic collaborations and its ENHANZE drug delivery technology. Analysts have mixed views, with Benchmark and H.C. Wainwright reiterating "Buy" ratings while Goldman Sachs maintains a "Sell" with a lower price target.
Halozyme, Other Hot Medical Plays Lead 22 Stocks Onto Best Stock Lists Like IBD 50, IPO Leaders
Twenty-two stocks, including four medical plays, have been added to various "best stock" lists, such as the IBD 50 and IPO Leaders, despite a general market downturn. Among these, Halozyme Therapeutics (HALO) reached a new high close. Other companies like Archrock (AROC) and several aerospace/defense stocks also made the cut.
Benchmark maintains Buy rating on Halozyme stock amid raised guidance
Benchmark has reiterated its 'Buy' rating and $75.00 price target for Halozyme Therapeutics (NASDAQ:HALO), attributing this to the company's raised financial guidance for 2025 and 2026. The firm cited recent license agreements with companies like Takeda and Merus, along with stronger royalty revenues, as key drivers for the positive outlook. Halozyme also revised its full-year FY25 total revenue guidance upwards and provided future revenue guidance exceeding consensus estimates for subsequent years.
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
Halozyme Therapeutics (HALO) is positioned to potentially beat its next earnings estimates, given its strong history of surpassing expectations in previous quarters. The company has a positive Zacks Earnings ESP of +4.28% and a Zacks Rank #3 (Hold), indicating a high probability of another positive earnings surprise. This analysis suggests investors should monitor HALO's upcoming report for continued outperformance.
Q1 EPS Estimate for Halozyme Therapeutics Raised by Analyst
Zacks Research has increased its Q1 2027 EPS estimate for Halozyme Therapeutics to $1.63 from $1.55, maintaining a "Hold" rating on the stock. This update follows Halozyme's strong previous earnings report where it surpassed expectations with an EPS of $1.72 and revenue of $354.3M. The company currently has an average analyst rating of "Hold" and has seen recent insider stock sales, while institutional ownership remains high.
Strs Ohio Sells 25,069 Shares of Halozyme Therapeutics, Inc. $HALO
Strs Ohio has significantly reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by selling 25,069 shares, bringing its total ownership to 2,930 shares valued at $215,000. Despite this, other institutional investors have either increased their holdings or acquired new stakes in the biopharmaceutical company. The article also provides an overview of recent analyst ratings, insider transactions, and the company's financial performance.
Halozyme Therapeutics (HALO) Is Up 6.6% After Lifting Guidance And Expanding ENHANZE Beyond Oncology
Halozyme Therapeutics has increased its 2026 revenue guidance to US$1.71 billion - US$1.81 billion, and projects 2025 revenue between US$1.39 billion and US$1.40 billion due to strong business momentum. The company's ENHANZE drug-delivery platform is expanding beyond oncology into inflammatory bowel disease and obesity, which analysts believe will be a significant driver of long-term growth. Investors are encouraged to consider both the upside potential from ENHANZE's expansion and the execution risks related to partner uptake and a leveraged balance sheet.
Is Halozyme Therapeutics (HALO) Still Attractive After Recent Drug Delivery Partnership-Driven Gains
Halozyme Therapeutics (HALO) has seen significant gains but its stock may still be undervalued according to Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) analyses. The DCF model suggests a 64.4% discount, estimating an intrinsic value of $201.64 per share against a market price of $71.71. Additionally, its P/E ratio of 14.16x is below the industry average and Simply Wall St's "Fair Ratio" of 19.85x.
